CA3002288C - Cytotoxic immunostimulating particles and uses thereof - Google Patents

Cytotoxic immunostimulating particles and uses thereof Download PDF

Info

Publication number
CA3002288C
CA3002288C CA3002288A CA3002288A CA3002288C CA 3002288 C CA3002288 C CA 3002288C CA 3002288 A CA3002288 A CA 3002288A CA 3002288 A CA3002288 A CA 3002288A CA 3002288 C CA3002288 C CA 3002288C
Authority
CA
Canada
Prior art keywords
rna
protamine
particles
cells
cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3002288A
Other languages
English (en)
French (fr)
Other versions
CA3002288A1 (en
Inventor
Steve Pascolo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech SE
Original Assignee
Biontech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech SE filed Critical Biontech SE
Publication of CA3002288A1 publication Critical patent/CA3002288A1/en
Application granted granted Critical
Publication of CA3002288C publication Critical patent/CA3002288C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA3002288A 2015-10-21 2016-10-20 Cytotoxic immunostimulating particles and uses thereof Active CA3002288C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2015/074386 2015-10-21
PCT/EP2015/074386 WO2017067592A1 (en) 2015-10-21 2015-10-21 Cytotoxic immunostimulating particles and uses thereof
PCT/EP2016/075146 WO2017068013A1 (en) 2015-10-21 2016-10-20 Cytotoxic immunostimulating particles and uses thereof

Publications (2)

Publication Number Publication Date
CA3002288A1 CA3002288A1 (en) 2017-04-27
CA3002288C true CA3002288C (en) 2023-06-27

Family

ID=54478716

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3002288A Active CA3002288C (en) 2015-10-21 2016-10-20 Cytotoxic immunostimulating particles and uses thereof

Country Status (6)

Country Link
US (2) US10980875B2 (OSRAM)
EP (1) EP3365010B1 (OSRAM)
JP (2) JP7098520B2 (OSRAM)
AU (1) AU2016341178B2 (OSRAM)
CA (1) CA3002288C (OSRAM)
WO (2) WO2017067592A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017067592A1 (en) 2015-10-21 2017-04-27 Biontech Ag Cytotoxic immunostimulating particles and uses thereof
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
MX2021003726A (es) 2018-10-01 2021-05-13 BioNTech SE Particulas de arn que comprenden polisarcosina.
WO2021001023A1 (en) * 2019-07-02 2021-01-07 Biontech Rna Pharmaceuticals Gmbh Rna formulations suitable for therapy
CN113577039A (zh) * 2021-07-01 2021-11-02 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 鱼精蛋白压缩dna后被红细胞膜包裹构成的纳米颗粒的应用及其制备方法
WO2025196322A2 (en) 2024-03-22 2025-09-25 BioNTech SE Cytotoxic polynucleotides, particles containing the cytotoxic polynucleotides and uses thereof
CN118845677B (zh) * 2024-07-09 2025-10-10 常州大学 一种阿霉素无定形固体分散体及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
AU6045094A (en) 1993-02-19 1994-09-14 Nippon Shinyaku Co. Ltd. Drug composition containing nucleic acid copolymer
US5457187A (en) * 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
CA2638906A1 (en) * 2006-01-26 2007-08-16 University Of Massachusetts Rna interference agents for therapeutic use
JP4936312B2 (ja) 2006-07-20 2012-05-23 株式会社島津製作所 新規な両親媒性物質、それを用いた薬剤搬送システム及び分子イメージングシステム
US20100310583A1 (en) * 2007-01-31 2010-12-09 Immune Disease Institute Let-7 microrna and mimetics thereof as therapeutics for cancer
WO2009088401A2 (en) 2007-09-24 2009-07-16 Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Immunostimulatory combinations of tlr ligands and methods of use
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
AU2009253160B2 (en) 2008-05-26 2015-03-05 Universitat Zurich Protamine/RNA nanoparticles for immunostimulation
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
WO2011069529A1 (en) * 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
US8889657B2 (en) 2011-08-31 2014-11-18 Mallinckrodt Llc Nanoparticle PEG modification with H-phosphonates
EP2942348B1 (en) 2014-05-07 2017-10-25 Johannes Gutenberg-Universität Mainz Thiol-protected amino acid derivatives and uses thereof
JP6586103B2 (ja) 2014-11-08 2019-10-02 国立大学法人 岡山大学 修飾ｒｎａを含有する分子集合体及びそれを用いたｒｎａ送達システム
WO2017067593A1 (en) 2015-10-21 2017-04-27 Biontech Ag Methods and means for inducing an immune response
WO2017067592A1 (en) 2015-10-21 2017-04-27 Biontech Ag Cytotoxic immunostimulating particles and uses thereof

Also Published As

Publication number Publication date
US12263215B2 (en) 2025-04-01
AU2016341178A1 (en) 2018-04-12
US20210205447A1 (en) 2021-07-08
EP3365010B1 (en) 2024-01-03
JP7098520B2 (ja) 2022-07-11
CA3002288A1 (en) 2017-04-27
WO2017068013A1 (en) 2017-04-27
JP7250986B2 (ja) 2023-04-03
WO2017067592A1 (en) 2017-04-27
US10980875B2 (en) 2021-04-20
WO2017068013A9 (en) 2018-03-22
US20180289797A1 (en) 2018-10-11
JP2018535206A (ja) 2018-11-29
AU2016341178B2 (en) 2023-02-23
JP2022130599A (ja) 2022-09-06
EP3365010C0 (en) 2024-01-03
EP3365010A1 (en) 2018-08-29

Similar Documents

Publication Publication Date Title
US12263215B2 (en) Cytotoxic immunostimulating particles and uses thereof
EP3758729B1 (en) Il-15 conjugates and uses thereof
US9636414B2 (en) Particles comprising single stranded RNA and double stranded RNA for immunomodulation
US20220347308A1 (en) Methods and means for inducing an immune response
IL291786A (en) Interleukin 10 conjugates and their use
US20170136129A1 (en) Stabilised Formulations of RNA
CA3138430A1 (en) Microparticles and nanoparticles having sulfate groups on the surface
US20200268895A1 (en) Immunostimulating-Toxic RNA In Alkaline Earth Metal Formulation
JP7520321B2 (ja) ＡタイプＣｐＧオリゴデオキシヌクレオチド含有脂質粒子
WO2022135667A1 (en) Therapeutic rna for treating cancer
WO2025196322A2 (en) Cytotoxic polynucleotides, particles containing the cytotoxic polynucleotides and uses thereof
US10172960B2 (en) Particles comprising single stranded RNA and double stranded RNA for immunomodulation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211014

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240930

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240930

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250925

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250925